» Articles » PMID: 28863752

Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa

Overview
Publisher Sage Publications
Date 2017 Sep 3
PMID 28863752
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The development of antiretroviral (ARV)-based prevention products has the potential to substantially change the HIV prevention landscape; yet, little is known about how appealing these products will be outside of clinical trials, as compared with the existing options.

Methods: We conducted a discrete choice experiment (DCE) to measure preferences for 5 new products among 4 important populations in the HIV response: adult men and women in the general population (aged 18 to 49 y), adolescent girls (aged 16 to 17 y), and self-identifying female sex workers (aged 18 to 49 y). We interviewed 661 self-reported HIV-negative participants in peri-urban South Africa, who were asked to choose between 3 unique, hypothetical products over 10 choice sets. Data were analyzed using multinomial, latent class and mixed multinomial logit models.

Results: HIV protection was the most important attribute to respondents; however, results indicate significant demand among all groups for multipurpose prevention products that offer protection from HIV infection, other STIs, and unwanted pregnancy. All groups demonstrated a strong preference for long-lasting injectable products. There was substantial heterogeneity in preferences within and across population groups.

Limitations: Hypothetical DCE data may not mirror real-world choices, and products will have more attributes in reality than represented in choice tasks. Background data on participants, including sensitive areas of HIV status and condom use, was self-reported.

Conclusions: These results suggest that stimulating demand for new HIV prevention products may require a more a nuanced approach than simply developing highly effective products. No single product is likely to be equally attractive or acceptable across different groups. This study strengthens the call for effective and attractive multipurpose prevention products to be deployed as part of a comprehensive combination prevention strategy.

Citing Articles

Acceptability of an annual tenofovir alafenamide implant for HIV prevention in South African women: findings from the CAPRISA 018 Phase I clinical trial.

Gengiah T, Heck C, Lewis L, Mansoor L, Harkoo I, Myeni N J Int AIDS Soc. 2025; 28(2):e26426.

PMID: 39981604 PMC: 11843155. DOI: 10.1002/jia2.26426.


A pilot cluster randomized controlled trial assessing uptake of PrEP and contraception in hair salons in South Africa.

Bassett I, Yan J, Govere S, Shezi S, Ngcobo L, Sagar S BMC Public Health. 2025; 25(1):524.

PMID: 39922997 PMC: 11806743. DOI: 10.1186/s12889-025-21718-3.


Assessing Non-Oral PrEP Alternatives Among Young Black Women in the Southern USA.

Denson D, Tesfaye C, Glusberg D, Schoua-Glusberg A, Betley V, Gale B J Racial Ethn Health Disparities. 2025; .

PMID: 39760837 DOI: 10.1007/s40615-024-02263-y.


Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods.

Bishopp C, Mungai-Barris Z, Briedenhann E, Donaldson E, Irungu E, Schwartz K Curr HIV/AIDS Rep. 2024; 22(1):7.

PMID: 39644439 PMC: 11625055. DOI: 10.1007/s11904-024-00715-y.


Pre-exposure prophylaxis implementation gaps among people vulnerable to HIV acquisition: a cross-sectional analysis in two communities in western Kenya, 2021-2023.

Romo M, Schluck G, Kosgei J, Akoth C, Bor R, Langat D J Int AIDS Soc. 2024; 27(11):e26372.

PMID: 39496511 PMC: 11534481. DOI: 10.1002/jia2.26372.